Gene Expression Analysis Market based on by Products (Consumable, Instruments), by Application (Drug Discovery, Diagnostics), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others), Regional Outlook– Global Forecast up to 2030
In the recent decade, the high cost of sequencing constituted a significant barrier to market expansion. The Human Genome Project needed USD 2.7 billion in funding in 2003 to sequence the first human genome. However, significant technical advancements in the field of genomics have occurred, with the goal of improving the speed and lowering the costs involved with sequencing.
For many years, the NHGRI (National Human Genome Research Institute, United States) has tracked sequencing prices at its many sponsored genome sequencing centres and calculated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, generating a finished human genome sequence would have cost more than USD 20-25 million, whereas by late 2015, the cost to generate a high-quality whole human genome sequence draft had fallen below USD 1,500, and the cost to generate a whole-exome sequence was generally less than USD 1,000.
Major firms in the gene expression sector are continually bringing new and improved technologies to the market. This enables the industry to see the introduction of more economical testing services. In January 2017, Illumina (US) unveiled the NovaSeq Series, which is predicted to reduce the cost of sequencing a genome/transcriptome to as little as USD 100 in the next years.
The lower cost of sequencing is likely to open up a slew of new prospects for healthcare players. For example, the low cost of sequencing would allow researchers to sequence the genomes of thousands of people, resulting in a better data set for determining the aetiology of diseases. Furthermore, the decreased cost would allow persons with uncommon disorders to be evaluated and treated more rapidly. As a result, the considerable decrease in sequencing costs is likely to be a major driver driving the growth of the gene expression analysis market.
Research Methodology:After secondary research provided a fundamental understanding of the worldwide Gene Expression Analysis Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Gene Expression Analysis Market , as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Gene Expression Analysis Market based on End User:Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Others
Gene Expression Analysis Market based on Product:Consumable
Instruments
Type
Polymerase Chain Reaction
Next Generation Sequencing
DNA Microarrays
Others
Gene Expression Analysis Market based on Application:Drug Discovery
Diagnostics
Gene Expression Analysis Market based on Geography:North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Rest of Europe (RoE)
Asia Pacific (APAC)
China
Japan
India
Australia
South Korea
Rest of Asia Pacific (RoAPAC)
Latin America (LATAM)
Brazil
Argentina
Rest of South America
Middle East and Africa (MEA)
UAE
Turkey
Saudi Arabia
South Africa
Rest of Middle East & Africa
The gene expression market is divided into product, application, end-user, and geographical segments. The market is divided into two categories: consumables and instruments. Polymerase chain reaction, next generation sequencing, DNA microarrays, and other tools are subdivided further. It is divided into two categories based on application: drug discovery and diagnostics. Pharmaceutical and biotechnology businesses, academic and research organisations, and others are the end users. It is examined in North America, Europe, Asia-Pacific, and Latin America.
Next-Generation Sequencing (NGS) is a technique for determining the sequence of DNA or RNA in order to analyse genetic changes linked with illness. It is also known as massively parallel sequencing since it allows the sequencing to determine the sequencing of millions of DNA sequences at the same time.
Next-generation sequencing is predicted to rise significantly throughout the forecast period due to reasons such as an increase in the application of NGS technology in clinical diagnostics, as well as the speed, affordability, and accuracy of the sequencing process. Furthermore, the benefit of NGS over Sanger's sequencing approach, which gives accuracy results with modest sample input, is boosting market expansion.
The growing usage of next-generation sequencing technology in applications such as biomarker identification, cancer research, and personalised medicine is driving market expansion. For example, the rapid emergence of next-generation sequencing technology has revolutionised genomics and medical diagnosis, shifting from a gene-by-gene approach to a precision model based on syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). According to the Centres for Disease Control and Prevention, more than 60 million people globally will have their genomes sequenced by 2025, as nations take the initiative to analyse big populations. Furthermore, cell-free plasma next-generation sequencing (cfNGS) is used to diagnose viral, bacterial, and fungal infections in the blood by detecting pathogen DNA.
Furthermore, several initiatives launched by universities, academic and research organisations, and research institutes to employ next-generation sequencing technology to pinpoint the underlying cause of illnesses are expected to boost the segment's growth. For example, Roche will deploy the AVENIO Edge System in December 2021 to improve next-generation sequencing (NGS) technology. Cerba Research, meanwhile, introduced two COVID-19 exploratory tools, PCR-based and Next-Generation Sequencing-based, in January 2021, to increase research for vaccine development against infectious illnesses, including COVID-19. The next-generation sequencing-based assay considerably simplified whole-genome sequencing of respiratory viruses including SARS-CoV-2. Such advancements provide a significant boost to clinical research and organisations who are using next-generation sequencing as their foundation for innovation.
The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some market players are QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Promega Corporation, and Luminex Corporation. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.
This report illustrates the most vital attributes of the Gene Expression Analysis Market, which are driving and providing opportunities.
This research gives an in-depth analysis of the Gene Expression Analysis Market growth on the basis of several segments in the market.
This report presents the predictions of the past and present trends of the Gene Expression Analysis Market.
This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Gene Expression Analysis Market.